tiprankstipranks
NurExone Biologic (TSE:NRX)
:NRX
Canadian Market

NurExone Biologic (NRX) Financial Statements

Compare
3 Followers

NurExone Biologic Financial Overview

NurExone Biologic's market cap is currently C$33.01M. The company's EPS TTM is C$-0.1; its P/E ratio is ―; NurExone Biologic is scheduled to report earnings on March 27, 2025, and the estimated EPS forecast is C$-0.03. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20Dec 19
Income Statement
Total Revenue
Gross Profit$ 17.66B$ 20.85B$ 13.61B$ 6.63B$ 4.07B
Operating Income$ 8.89B$ 13.66B$ 6.52B$ 1.99B$ -69.00M
EBITDA$ 14.80B$ 17.66B$ 9.64B$ 4.30B$ 2.43B
Net Income$ 15.00B$ 12.56B$ 5.52B$ 721.00M$ -862.00M
Balance Sheet
Cash & Short-Term Investments$ ―$ ―$ ―$ ―$ ―
Total Assets$ 106.62B$ 82.34B$ 62.13B$ 52.15B$ 25.72B
Total Debt$ 2.37B$ 1.50B$ 8.87B$ 2.13B$ 1.78B
Net Debt$ -26.72B$ -20.68B$ -8.83B$ -17.25B$ -4.48B
Total Liabilities$ 43.01B$ 36.44B$ 31.12B$ 28.47B$ 26.20B
Stockholders' Equity$ ―$ ―$ ―$ ―$ ―
Cash Flow
Free Cash Flow$ 4.36B$ 7.57B$ 5.01B$ 2.55B$ 1.07B
Operating Cash Flow$ 13.26B$ 14.72B$ 11.50B$ 5.71B$ 2.40B
Investing Cash Flow
Financing Cash Flow
Currency in USD

NurExone Biologic Earnings and Revenue History

NurExone Biologic Debt to Assets

NurExone Biologic Cash Flow

NurExone Biologic Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis